百时美施贵宝Bristol Myers Squibb（BMY）2025年第三季度业绩报告「NYSE」（英文版）（20页）.pdf

1、 1 Bristol Myers Squibb Reports Third Quarter Financial Results for 2025 Performance Marked by Continued Growth Portfolio Momentum,Pipeline Advancements and Strategic Business Development Third quarter revenues increased 3%(+2%Ex-FX)to$12.2 billion Growth Portfolio revenues increased 18%(+17%Ex-FX)t

2、o$6.9 billion GAAP EPS was$1.08 and non-GAAP EPS was$1.63;Both figures include net impact of$(0.20)due to the Acquired IPRD charges and licensing income Raising 2025 revenue guidance to a range of$47.5 billion to$48.0 billion;Updating non-GAAP EPS range to$6.40 to$6.60,inclusive of an$(0.80)per shar

3、e net impact from Acquired IPRD charges and licensing income(PRINCETON,N.J.,October 30,2025)Bristol Myers Squibb(NYSE:BMY)today reports results for the third quarter of 2025.“We delivered strong results this quarter as a result of continued execution across the business and ongoing Growth Portfolio

4、momentum,”said Christopher Boerner,Ph.D.,board chair and chief executive officer,Bristol Myers Squibb.“Were focused on building for the future by accelerating innovation,advancing our pipeline,staying agile and delivering more transformational medicines to more patients.Third Quarter Results$in mill

5、ions,except per share amounts 2025 2024 Change Change Excl.FX*Total Revenues$12,222$11,892 3%2%Earnings/(Loss)Per Share-GAAP*1.08 0.60 81%N/A Earnings/(Loss)Per Share-Non-GAAP*1.63 1.80 (9)%N/A Acquired IPRD Charges and Licensing Income Net Impact on Earnings/(Loss)Per Share (0.20)(0.09)N/A N/A*GAAP

6、 and Non-GAAP earnings/(loss)per share include the net impact of Acquired IPRD charges and licensing income.*See Use of Non-GAAP Financial Information.2 THIRD QUARTER RESULTS All comparisons are made versus the same period in 2024 unless otherwise stated.Growth Portfolio revenues of$6.9 billion incr